Literature DB >> 30674421

Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.

Bingyi Yang1, Yuhui Xu1, Qin Zhu2, Liying Xie3, Weiwei Shan3, Chengcheng Ning3, Bingying Xie3, Yue Shi3, Xuezhen Luo1, Hongwei Zhang4, Xiaojun Chen5.   

Abstract

OBJECTIVE: This study aimed to evaluate the efficacy of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young patients with endometrial atypical hyperplasia (EAH) and early stage endometrial cancer (EEC) who wished to preserve their fertility.
METHODS: Patients with EAH (n = 120) or well-differentiated EEC (n = 40, FIGO stage IA, without myometrial invasion) were retrospectively included. All patients received constant oral progestin combined with hysteroscopic evaluation every 3 months until achieving complete response (CR). The location, number and size of each suspected lesion or cluster were detailly recorded during the hysteroscopy.
RESULTS: The median age was 32.0 year-old (range, 22-47 year-old). Totally 148 patients (97.4%) achieved CR while 3 EAH and 1 EEC patients presented with disease progression, and 8 patients were still in treatment. The mean treatment duration for achieving CR was 6.7 ± 0.3 months (range, 1-18 months). After adjusting for patient age, body mass index (BMI), history of pregnancy and type of conservative therapies, lesion size ≤2 cm (OR, 0.701; 95% CI, 0.496-0.991; P = 0.045) was significantly correlated with shorter treatment time to achieve CR. Among 60 patients attempted to conceive after achieving CR, 45.0% (15/60) had been pregnant, 25.0% (15/60) delivered live birth, 13.3% (8/60) are still in pregnancy, while 6.7% experienced spontaneous abortion.
CONCLUSION: Comprehensive hysteroscopic evaluation and lesion resection plus progestin therapy seem to be an effective and safe fertility sparing therapy for patients with EAH or EEC. Endometrial lesion size ≤2 cm correlated with a shorter treatment period to achieve CR.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Conservative treatment; Endometrial atypical hyperplasia; Endometrial carcinoma; Hysteroscopy

Mesh:

Substances:

Year:  2019        PMID: 30674421     DOI: 10.1016/j.ygyno.2019.01.014

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  19 in total

1.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

2.  LASS2 mediates Nrf2-driven progestin resistance in endometrial cancer.

Authors:  Bin Yang; Meiyan Hu; Yue Fu; Di Sun; Wenxin Zheng; Hong Liao; Zhenbo Zhang; Xiong Chen
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

3.  LNG-IUS combined with progesterone ameliorates endometrial thickness and pregnancy outcomes of patients with early-stage endometrial cancer or atypical hyperplasia.

Authors:  Fang Fang; Hao Xu; Ling Wu; Linyi Hu; Ying Liu; Yinnan Li; Chunhua Zhang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

4.  Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment.

Authors:  Shuang Zhou; Zhiying Xu; Bingyi Yang; Jun Guan; Weiwei Shan; Yue Shi; Xiaojun Chen
Journal:  J Gynecol Oncol       Date:  2021-07       Impact factor: 4.401

5.  Fertility-sparing treatment in early endometrial cancer: current state and future strategies.

Authors:  Andreas Obermair; Eva Baxter; Donal J Brennan; Jessica N McAlpine; Jennifer J Muellerer; Frédéric Amant; Mignon D J M van Gent; Robert L Coleman; Shannon N Westin; Melinda S Yates; Camilla Krakstad; Monika Janda
Journal:  Obstet Gynecol Sci       Date:  2020-07-08

6.  Usefulness of biopsy by office hysteroscopy for endometrial cancer: A case report.

Authors:  Kenbun Sone; Satoko Eguchi; Kayo Asada; Futaba Inoue; Yuichiro Miyamoto; Michihiro Tanikawa; Tetsushi Tsuruga; Mayuyo Mori-Uchino; Yoko Matsumoto; Osamu Hiraike-Wada; Katsutoshi Oda; Yutaka Osuga; Tomoyuki Fujii
Journal:  Mol Clin Oncol       Date:  2020-05-27

7.  Automated system for diagnosing endometrial cancer by adopting deep-learning technology in hysteroscopy.

Authors:  Yu Takahashi; Kenbun Sone; Katsuhiko Noda; Kaname Yoshida; Yusuke Toyohara; Kosuke Kato; Futaba Inoue; Asako Kukita; Ayumi Taguchi; Haruka Nishida; Yuichiro Miyamoto; Michihiro Tanikawa; Tetsushi Tsuruga; Takayuki Iriyama; Kazunori Nagasaka; Yoko Matsumoto; Yasushi Hirota; Osamu Hiraike-Wada; Katsutoshi Oda; Masanori Maruyama; Yutaka Osuga; Tomoyuki Fujii
Journal:  PLoS One       Date:  2021-03-31       Impact factor: 3.240

Review 8.  Hysteroscopy in the management of endometrial hyperplasia and cancer in reproductive aged women: new developments and current perspectives.

Authors:  Salvatore Giovanni Vitale; Gaetano Riemma; Jose Carugno; Benito Chiofalo; George Angelos Vilos; Stefano Cianci; Mehmet Sukru Budak; Bernardo Portugal Lasmar; Antonio Raffone; Ilker Kahramanoglu
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

Review 9.  Fertility issue in early stage endometrial cancer patients.

Authors:  Hasan Onur Topçu; Cihan Kaya; Engin Oral
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

10.  Weight Loss Improves Pregnancy and Livebirth Outcomes in Young Women with Early-Stage Endometrial Cancer and Atypical Hyperplasia.

Authors:  Yanfang Zhang; Dan Li; Qi Yan; Xueru Song; Wenyan Tian; Yingmei Wang; Fei Teng; Likun Wei; Jinghua Wang; Huiying Zhang; Fengxia Xue
Journal:  Cancer Manag Res       Date:  2021-07-14       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.